LAMICTAL - LAMICTAL ODT - Efficacy in Pediatric Patients ≥ 2 Years of Age

Main Page	\|	Healthcare Professionals	\|	Patients & Caregivers

Important Safety Information

Efficacy & Tolerability Overview>

Efficacy in Pediatric Patients

Tolerability in Pediatric Patients>

Efficacy in Adult Patients>

Tolerability in Adult Patients>

Efficacy in Pediatric Patients
(≥2 Years of Age)

Think ahead—an AED profile for their years of development

RESULTS FROM: DUCHOWNY ET AL. Neurology. 1999;53:1724-1731. Study design: LAMICTAL or placebo was added to existing therapy of up to 2 concurrent AEDs in an 18-week, multicenter, double-blind, placebo-controlled trial of 199 pediatric patients (aged 2 to 16 years) with partial seizures inadequately controlled on existing therapy (≥4 seizures/month). The maintenance dose of LAMICTAL was based on weight and concomitant medications.

Click here for Interactive Pediatric Dosing Illustrator.

RESULTS FROM: TREVATHAN ET AL. Pediatrics. 2006; 118;371-378. Study design: Subanalysis of children and adolescents, aged 2 to 20 years (n=45) from a randomized, blinded, placebo-controlled clinical trial of 117 patients, aged 2 to 55 years with PGTC seizures inadequately controlled on 1 or 2 current antiepileptic drugs.

RESULTS FROM: MOTTE ET AL. N Engl J Med. 1997;337:1807-1812. Study design: Multicenter, double-blind, placebo-controlled trial of 169 patients (aged 3 to 25) with LGS inadequately controlled (average of ≥1 seizure every other day) on existing therapy. At baseline, frequency ranged from 3 to 249 major seizures/week for patients in the group taking LAMICTAL and from 2 to 593 major seizures/week for patients in the placebo group. After a 4-week placebo baseline, LAMICTAL or placebo was added to existing therapy of up to 3 concomitant AEDs for 16 weeks. The maintenance dose of LAMICTAL was based on weight and concomitant medications.

References: 1. Duchowny M, Pellock JM, Graf WD, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology. 1999;53:1724-1731. 2. Trevathan E, Kerls SP, Hammer AE, Vuong A, Messenheimer JA. LAMICTAL (lamotrigine) as adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Pediatrics. 2006; 118:e371-e378. 3. Motte J, Trevathan E, Arvidsson JFV, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med. 1997;337:1807-1812.

Safety and effectiveness of LAMICTAL and LAMICTAL ODT have not been established 1) as initial monotherapy, 2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate, or 3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.

EFFICACY AND TOLERABILITY

Learn more about the efficacy and tolerability your adult patients need.

Important Safety Information About LAMICTAL and LAMICTAL ODT

•

LAMICTAL ODT is another form of LAMICTAL.

•

Cases of life-threatening serious rashes, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and/or rash-related death, have been caused by LAMICTAL. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:

– coadministration with valproate

– exceeding recommended initial dose of LAMICTAL

– exceeding recommended dose escalation of LAMICTAL

•

Benign rashes are also caused by LAMICTAL; however, it is not possible to predict which rashes will prove to be serious or life-threatening. LAMICTAL should be discontinued at the first sign of rash, unless the rash is clearly not drug-related (see Boxed Warning in Prescribing Information).

•

Hypersensitivity reaction may be fatal or life-threatening. Early signs of hypersensitivity (eg, fever, lymphadenopathy) may present without rash; if signs present, patient should be evaluated immediately. LAMICTAL should be discontinued if alternate etiology for hypersensitivity signs is not found.

•

Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (eg, fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately.

•

Acute multiorgan failure has resulted (some cases fatal).

•

Blood dyscrasias (eg, neutropenia, thrombocytopenia, pancytopenia) may result either with or without an associated hypersensitivity syndrome.

•

Antiepileptic drugs, including LAMICTAL ODT, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.

•

Patients treated with any antiepileptic drug for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

•

Patients, their caregivers, and families should be informed that antiepileptic drugs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

Medication Guide for LAMICTAL^® (lamotrigine) Tablets and LAMICTAL^® ODT™ (lamotrigine) Orally Disintegrating Tablets

Complete Prescribing Information and Medication Guide for LAMICTAL^® (lamotrigine) Tablets and LAMICTAL^® ODT™ (lamotrigine) Orally Disintegrating Tablets including Boxed Warning